| MET exon 14 mutations in non–small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression MM Awad, GR Oxnard, DM Jackman, DO Savukoski, D Hall, P Shivdasani, ... Journal of clinical oncology, 2016 | 601 | 2016 |
| Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer AG Sacher, C Paweletz, SE Dahlberg, RS Alden, A O’Connell, N Feeney, ... JAMA oncology 2 (8), 1014-1022, 2016 | 580 | 2016 |
| Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ... JAMA oncology 4 (11), 1527-1534, 2018 | 541 | 2018 |
| High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia A Gutierrez, T Sanda, R Grebliunaite, A Carracedo, L Salmena, Y Ahn, ... Blood, The Journal of the American Society of Hematology 114 (3), 647-650, 2009 | 487 | 2009 |
| Outcomes for elderly, advanced-stage non–small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern … SS Ramalingam, SE Dahlberg, CJ Langer, R Gray, CP Belani, ... Journal of Clinical Oncology 26 (1), 60-65, 2008 | 450 | 2008 |
| Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers D Rangachari, N Yamaguchi, PA VanderLaan, E Folch, A Mahadevan, ... Lung Cancer 88 (1), 108-111, 2015 | 415 | 2015 |
| Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes SE Lipshultz, TL Miller, RE Scully, SR Lipsitz, N Rifai, LB Silverman, ... Journal of clinical oncology 30 (10), 1042, 2012 | 345 | 2012 |
| Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions GR Oxnard, PC Lo, M Nishino, SE Dahlberg, NI Lindeman, M Butaney, ... Journal of Thoracic Oncology 8 (2), 179-184, 2013 | 320 | 2013 |
| Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs JJ Lin, S Cardarella, CA Lydon, SE Dahlberg, DM Jackman, PA Jänne, ... Journal of Thoracic Oncology 11 (4), 556-565, 2016 | 307 | 2016 |
| Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute … LM Vrooman, KE Stevenson, JG Supko, J O'Brien, SE Dahlberg, ... Journal of Clinical Oncology 31 (9), 1202, 2013 | 304 | 2013 |
| Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis A Mauguen, C Le Péchoux, MI Saunders, SE Schild, AT Turrisi, ... Journal of Clinical Oncology 30 (22), 2788, 2012 | 300 | 2012 |
| Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia DJ DeAngelo, KE Stevenson, SE Dahlberg, LB Silverman, S Couban, ... Leukemia 29 (3), 526-534, 2015 | 295 | 2015 |
| Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix AA Wright, BE Howitt, AP Myers, SE Dahlberg, E Palescandolo, ... Cancer 119 (21), 3776-3783, 2013 | 290 | 2013 |
| Clinical course of advanced non–small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on … SE Dahlberg, AB Sandler, JR Brahmer, JH Schiller, DH Johnson Journal of Clinical Oncology 28 (6), 949, 2010 | 288 | 2010 |
| Safety of programmed Death–1 pathway inhibitors among patients with Non–Small-Cell lung cancer and preexisting autoimmune disorders GC Leonardi, JF Gainor, M Altan, S Kravets, SE Dahlberg, L Gedmintas, ... Journal of Clinical Oncology 36 (19), 1905, 2018 | 279 | 2018 |
| The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute … RF Grace, SE Dahlberg, D Neuberg, SE Sallan, JM Connors, EJ Neufeld, ... British journal of haematology 152 (4), 452-459, 2011 | 251 | 2011 |
| Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer A Calles, X Liao, LM Sholl, SJ Rodig, GJ Freeman, M Butaney, C Lydon, ... Journal of Thoracic Oncology 10 (12), 1726-1735, 2015 | 238 | 2015 |
| Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression EJ Aguilar, B Ricciuti, JF Gainor, KL Kehl, S Kravets, S Dahlberg, ... Annals of Oncology 30 (10), 1653-1659, 2019 | 225 | 2019 |
| Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual … A Mauguen, JP Pignon, S Burdett, C Domerg, D Fisher, R Paulus, ... The Lancet Oncology 14 (7), 619-626, 2013 | 225 | 2013 |
| Immune checkpoint inhibitor outcomes for patients with Non–Small-Cell lung cancer receiving baseline corticosteroids for palliative versus Nonpalliative indications B Ricciuti, SE Dahlberg, A Adeni, LM Sholl, M Nishino, MM Awad Journal of Clinical Oncology 37 (22), 1927-1934, 2019 | 215 | 2019 |
Donna NeubergDana-Farber Cancer Institute在 jimmy.harvard.edu 的电子邮件经过验证
